Veracyte

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Veracyte and other ETFs, options, and stocks.

About VCYT

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. 

CEO
Marc A. Stapley
CEOMarc A. Stapley
Employees
755
Employees755
Headquarters
South San Francisco, California
HeadquartersSouth San Francisco, California
Founded
2006
Founded2006
Employees
755
Employees755

VCYT Key Statistics

Market cap
3.59B
Market cap3.59B
Price-Earnings ratio
41.60
Price-Earnings ratio41.60
Dividend yield
Dividend yield
Average volume
1.09M
Average volume1.09M
High today
$46.00
High today$46.00
Low today
$44.87
Low today$44.87
Open price
$45.46
Open price$45.46
Volume
1.40M
Volume1.40M
52 Week high
$50.71
52 Week high$50.71
52 Week low
$22.61
52 Week low$22.61

Stock Snapshot

As of today, Veracyte(VCYT) shares are valued at $45.10. The company's market cap stands at 3.59B, with a P/E ratio of 41.60.

On 2026-05-22, Veracyte(VCYT) stock traded between a low of $44.87 and a high of $46.00. Shares are currently priced at $45.10, which is +0.5% above the low and -2.0% below the high.

The Veracyte(VCYT)'s current trading volume is 1.4M, compared to an average daily volume of 1.09M.

In the last year, Veracyte(VCYT) shares hit a 52-week high of $50.71 and a 52-week low of $22.61.

In the last year, Veracyte(VCYT) shares hit a 52-week high of $50.71 and a 52-week low of $22.61.

VCYT News

Simply Wall St 2d
Why Veracyte Is Up 5.4% After Medicare Backs Its TrueMRD Bladder Cancer Test - simplywall.st

...

Why Veracyte Is Up 5.4% After Medicare Backs Its TrueMRD Bladder Cancer Test - simplywall.st
Simply Wall St 5d
A Look At Veracyte Valuation After Medicare Coverage For TrueMRD Cancer Monitoring Test

Veracyte (VCYT) has drawn fresh attention after announcing Medicare coverage from CMS for its TrueMRD Monitoring Test for muscle-invasive bladder cancer, with c...

A Look At Veracyte Valuation After Medicare Coverage For TrueMRD Cancer Monitoring Test

Analyst ratings

82%

of 11 ratings
Buy
81.8%
Hold
9.1%
Sell
9.1%

People also own

Based on the portfolios of people who own VCYT. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.